SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cor Therapeutics Inc. (CORR)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (445)5/12/1999 2:59:00 PM
From: John Patterson  Read Replies (1) of 712
 
I agree with you Peter, bleeding has not been a major problem with ReoPro, at least not for the cardiologist. However, the bleeding associated with emergency open-heart surgery can be significant.
Many of the patients that we receive after failed angioplasty, and/or stenting have been on asprin at home, have had heparin during their cath, received TPA in the ER and then ReoPro in an attempt to keep the artery patent.
These patients may require multiple transfusions of RBC's, platlets, and fresh frozen plasma in addition to a host of drugs such as DDAVP, Aprotinin, Amicar and protamine in an attempt to restore hemostasis.
Of course, the effect of Integrillin on platlet adhesion is profound also.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News